Business context and reporting period
Filing identity: The supplied filing is Visualant, Inc.’s Form 10-K, not a filing identified as USBC, Inc. It covers the fiscal year ended September 30, 2016; it is an annual report, not a standalone fourth-quarter report.
Visualant develops ChromaID, a light-based technology intended to identify and authenticate substances. Its subsidiary TransTech, a distributor of personnel-identification products, generated substantially all company revenue. ChromaID had produced only minimal revenue, and its Liquid Lab Kit remained at the prototype stage.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $6.024 million | $6.291 million |
| Gross profit / margin | $988,000 / 16.4% | $1.016 million / 16.2% |
| Research and development | $326,000 | $363,000 |
| Selling, general and administrative | $3.355 million | $2.984 million |
| Operating loss | $(2.693) million | $(2.330) million |
| Net loss | $(1.746) million | $(2.631) million |
| Cash used in operating activities | $(3.374) million | $(240,000) |
- Revenue fell 4.2%, primarily due to lower TransTech product sales. Gross margin edged up from 16.2% to 16.4%.
- Net loss improved, but mainly because of a $2.560 million noncash gain from revaluing derivative liabilities. This was partly offset by a $1.278 million loss on debt conversion. Operating loss widened.
- Cash was $188,000 at year-end. Current assets were $1.313 million versus current liabilities of $5.440 million; management reported a working-capital deficit of approximately $3.982 million, excluding derivative liabilities.
- Year-end liabilities included $909,500 of convertible notes and $1.170 million of notes payable, all classified as current. Trade accounts payable were $1.984 million, and accrued expenses due to related parties were $1.109 million.
- Financing activities provided $3.497 million, including proceeds from stock and preferred-stock sales, warrant exercises, and convertible notes.
Changes, outlook, risks and unusual items
- SG&A rose $371,000, with higher business-development, investor-relations and consulting costs. R&D spending declined $37,000.
- Management expected continued losses while commercializing ChromaID and stated that year-end cash would fund operations only through January 31, 2017. It said additional financing was needed; the auditor’s report highlighted substantial doubt about the company’s ability to continue as a going concern.
- In August 2016, Visualant raised $1.25 million through Series C preferred stock and $500,000 from a common-stock sale, each accompanied by warrants at a $0.70 exercise price. The Series C carried an 8% yield and conversion features; accounting for its beneficial conversion feature generated a $1.16 million preferred-stock dividend charge.
- Subsequent events included a planned best-efforts Series D offering of up to $2.5 million, additional note financing, and conversion of $695,000 of notes into shares and warrants. These transactions may materially dilute existing shareholders.
- Related-party financing is significant: the company reported $1.547 million owed to CEO Ronald Erickson or affiliated entities. Certain notes were secured or could obtain a second lien; subsequent amendments extended some due dates.
- Management identified a material weakness in internal controls and concluded disclosure controls were ineffective, citing the lack of an audit committee financial expert. Management expected to appoint an independent financial expert.
- Other key risks include early-stage commercialization and uncertain customer adoption, reliance on partners and concentrated TransTech vendors, financing availability, potential dilution, and dependence on intellectual-property protections. The filing reported no material pending legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: the filing names Visualant, Inc. (ticker VSUL), which does not match the request metadata naming USBC, Inc.
- Review the audited financial statements and notes for the full debt maturity schedule, covenant status, collateral, and subsequent extensions or conversions; the filing cites different debt totals in different sections.
- Verify post-year-end cash, financing proceeds, payment obligations, and whether the company obtained funding beyond management’s stated January 31, 2017 cash runway.
- Reconcile the share counts and potential dilution from outstanding warrants, preferred-stock conversions, and convertible notes; the filing presents figures as of different dates and some amounts are described as unknown.
- Assess whether ChromaID has secured meaningful paying customers or licenses, and whether the company has remediated its disclosed control weakness.